Found 25 cardiology trials
A listing of cardiology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group, event-driven, superiority, group sequential study to evaluate the efficacy and safety of milvexian in participants enrolled within 7 days of an Acute Coronary Syndrome. Participants will receive either milvexian/ placebo on a background of standard-of-care antiplatelet therapy. The total …
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of amyloid depleter ALXN2220 compared to placebo in adult participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).Approximately 1000 participants will be enrolled and randomized to receive either ALXN2220 or placebo in a 2:1 ratio. Participants will receive …
This is a prospective, multicenter,randomized, nonblinded study to evaluate the safety and effectiveness of the Aortix System versus standard of care medical therapy in patients hospitalized with ADHF and persistent congestion despite usual medical management and who are not being considered for nearterm advanced HF therapy (i.e., LVAD placement or …
To evaluate the efficacy of NTLA-2001, as measured by the composite risk of CV-related mortality and CV events (urgent HF visits and hospitalizations due to HF, MI, arrhythmia, or stroke), compared to placebo Composite endpoint comprising Cardiovascular related mortality and frequency and timing of Cardiovascular events (urgent Heart Failure visits …
This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of repeat doses of IgPro20 in subjects with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome). Eligible subjects will be randomized in a 2:1 ratio to receive subcutaneous (SC) infusions of IgPro20 …
The AMPLIFY EP Registry is an observational, prospective, multi-center, non-randomized registry designed to obtain real world clinical experience with the TactiFlex Catheter Ablation system in the treatment of Atrial Fibrillation. Patient assessments will occur at pre- procedure and procedure, and 1 year post ablation.
DPP4 is an enzyme that breaks down proteins that may affect blood sugar and the heart. We will recruit individuals from the Penn Biobank (cases, controls). Participants will be asked to complete a meal test, DXA, and echocardiogram with exercise. A cardiac MRI and related pilot study are optional.
The REAL AF Registry is an observational, prospective, non-randomized registry designed to find out more about the outcomes for patients who receive an ablation as treatment for Paroxysmal Atrial Fibrillation (PAF) and Persistent (PsAF) Atrial Fibrillation. The registry aims to better understand real-world information for patients with this disorder. Eligible …
The OPTIMIZER® INTEGRA CCM-D System, also known as a “Cardiac Contractility Modulation – Defibrillator” is an investigational device system that combines CCM® therapy and ICD therapy into one device. CCM therapy has been shown to improve heart failure symptoms. This clinical trial is designed to determine if the OPTIMIZER® INTEGRA …
At home care (AHC) Artificial Intelligence Electrocardiogram (AI-ECG) can improve cardiac screening by echocardiogram for first degree relatives (FDR) of patients with dilated cardiomyopathy (DCM). Probands will contact their FDRs about testing with an AI-ECG mobile device. This study compares the impact of screening FDR of probands with DCM using …
